Oxelumab is a monoclonal antibody that has been investigated for its potential therapeutic applications, particularly in the treatment of autoimmune diseases. As a biologic, it is designed to target specific proteins in the immune system, thereby modulating immune responses. The chemical structure of Oxelumab includes a complex arrangement of amino acids that form its active sites, allowing it to bind selectively to its target. Its mechanism of action typically involves inhibiting certain pathways that contribute to inflammation and immune dysregulation. Oxelumab is administered via injection, and its pharmacokinetics can vary based on factors such as dosage and patient characteristics. Safety and efficacy profiles are established through clinical trials, which assess potential side effects and therapeutic benefits. As with many biologics, storage conditions are critical, often requiring refrigeration to maintain stability. Overall, Oxelumab represents a targeted approach in the realm of immunotherapy, reflecting ongoing advancements in the treatment of chronic inflammatory conditions.

Oxelumab

1186098-83-8: R 4930, Immunoglobulin, anti-(human antigen OX-40 ligand) (human monoclonal γ-chain), disulfide with human monoclonal κ-chain, dimer, huMAb OX 40L, Oxelumab, Ro 49-89991

Oxelumab (R 4930) is a human monoclonal antibody for OX40L. Oxelumab could be used to study asthma.

Anti-OX-40 ligand human monoclonal antibody; asthma treatment

CAS 1186098-83-8: Oxelumab

Oxelumab

Ref: TM-T76891

Oxelumab

Ref: 3D-CLA1258